Caroline A. Larregieu

Drug Discovery and Regulatory Considerations for Improving In Silico and In Vitro Predictions that Use Caco-2 as a Surrogate for Human Intestinal Permeability Measurements

Caroline A. Larregieu, Leslie Z. Benet · The AAPS Journal · 2013 · 157 citations · Full text

Pharmacy, Pharmacology, Bioavailability +16

Distinguishing between the Permeability Relationships with Absorption and Metabolism To Improve BCS and BDDCS Predictions in Early Drug Discovery

Caroline A. Larregieu, Leslie Z. Benet · Molecular Pharmaceutics · 2014 · 76 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

The FDA Should Eliminate the Ambiguities in the Current BCS Biowaiver Guidance and Make Public the Drugs for Which BCS Biowaivers Have Been Granted

Leslie Z. Benet, Caroline A. Larregieu · Clinical Pharmacology & Therapeutics · 2010 · 40 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy

Wei-cong Ma, Qing Zhang, Hui Li et al. · International Journal of Pharmaceutics · 2013 · 22 citations

Pharmacy, Pharmacokinetics, Pharmacology +12

Development of Synthetic Peptide-Modified Liposomes with LDL Receptor Targeting Capacity and Improved Anticancer Activity

Mei Liu, Wei Li, Caroline A. Larregieu et al. · Molecular Pharmaceutics · 2014 · 21 citations

Pharmacy, Pharmaceutics, Pharmacology +17